Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223034 · ClinicalTrials.gov registry record · Phase 1
A Study of 177Lu-PSMA-617 in People With Gliomas
A Phase 1 study of Glioma and Glioblastoma, IDH-wildtype, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT07223034 is a Phase 1 study of Glioma and Glioblastoma, IDH-wildtype that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07223034, a Phase 1 study of Glioma and Glioblastoma, IDH-wildtype, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG 177Lu-PSMA-617
- DIAGNOSTIC_TEST 68Ga-PSMA-PET scan/ MRI
- BEHAVIORAL Quality of Life Questionnaires
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223034
The ClinicalTrials.gov registry entry for NCT07223034 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT07223034 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07223034 about?
NCT07223034 is a clinical study titled "A Study of 177Lu-PSMA-617 in People With Gliomas". The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
What is the current status of trial NCT07223034?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-10-27. Estimated completion is 2027-10.
What conditions does trial NCT07223034 study?
This clinical trial studies the following conditions: Glioma, Glioblastoma, IDH-wildtype, Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4).
What interventions are being tested in trial NCT07223034?
The interventions under investigation include: Temozolomide (DRUG), 177Lu-PSMA-617 (DRUG), 68Ga-PSMA-PET scan/ MRI (DIAGNOSTIC_TEST), Quality of Life Questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT07223034?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223034 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
-
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.